CHMP recommends pirtobrutinib for CLL across all treatment lines after phase 3 trials showed strong efficacy and a favorable safety profile.
|Videos|June 26, 2023
A Phase 2 Study of Zanubrutinib in Previously Treated B-Cell Malignancies Intolerant to Ibrutinib and/or Acalabrutinib: Preliminary Results for Patients With CLL/SLL
Key opinion leader Mazyar Shadman, MD, MPH, reviews data from a clinical trial studying zanubrutinib in the context of ibrutinib- and/or acalabrutinib-intolerant CLL/SLL.
Advertisement
Advertisement
Related to this article
Advertisement
Advertisement
Trending on OncLive
1
Bexobrutideg Could Pave the Way for BTK Degraders in R/R Chronic Lymphocytic Leukemia
2
Domvanalimab/Zimberelimab Plus Chemotherapy Fails to Improve OS in HER2-Negative Gastroesophageal Adenocarcinoma
3
Extended FOLFOX, Atezolizumab Duration Linked With Improved DFS in Stage III dMMR Colon Cancer
4
ESR1 Mutations Steer the Oral SERD Story in Breast Cancer: With Sara Nunnery, MD, MSCI; and MinhTri Nguyen, MD
5